ROR1 and cancer: These treatments include but are not limited to: antibody-drug conjugates (ADC) such as Zilovertamab Vedotin (NCT04504916 trial, Merck & Co) and NBE-002 (NCT04441099, NBE Therapeutics AG) in solid tumours, chimeric antigen receptor genetically modified T-cell (CAR-T) therapies in select ROR1 positive cases from haematological and solid tumour indications (NCT02706392, Fred Hutchinson cancer research Center), and a bi-specific CD3 T-cell engager (TCE) NVG-111 in ROR1 positive patients from haematological and solid tumour indications (NCT04763083, NovalGen Ltd).